MannKind (MNKD)
(Delayed Data from NSDQ)
$5.19 USD
+0.12 (2.37%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $5.20 +0.01 (0.19%) 7:02 PM ET
1-Strong Buy of 5 1
D Value B Growth B Momentum C VGM
Brokerage Reports
MannKind Corporation [MNKD]
Reports for Purchase
Showing records 101 - 120 ( 229 total )
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Recent Drug Launch Weekly Retail Sales Tracker - Week Ended March 6
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Discontinuation of Coverage of the Biotech Sector
Provider: Brinson Patrick Securities Corporation
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
2Q''14 Update; Model Changes from SNY Deal
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Global Sanofi Deal: Finds Ideal Strategic Partner
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
A Giant Leap - FDA approves Afrezza for type 1 and type 2 diabetes
Provider: Griffin Securities, Inc.
Analyst: MARKEY K
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Raising Price Target to $15.00 on FDA approval of Afrezza
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
1Q''14 Update: Eagerly Anticipating Afrezza Approval.
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
1Q''14 Update: Eagerly Anticipating Afrezza Approval
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C